Engineered immune cells take aim at Hard-to-Treat cancers
NCT ID NCT04427449
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new treatment called 4SCAR-CD44v6 T cells for people with cancers that have a specific protein called CD44v6. The therapy uses a patient's own immune cells, modified to better recognize and attack cancer cells. The trial will enroll 100 participants to check safety and see if the treatment shrinks tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 4SCAR-CD44v6 T cells (a type of immune cell therapy)
- What this could lead to
- If successful, this could offer a new treatment option for certain cancers that express the CD44v6 protein.
- What could go wrong
- This is an early phase 1/2 trial with only 100 participants, so results are preliminary. There may be side effects from the cell therapy, and it may not work for all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shenzhen Geno-immune Medical Institute
RECRUITINGShenzhen, Guangdong, 518000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a new tracer light up hidden prostate cancer?
- Can a personalized exercise program boost recovery in cancer survivors?
- Could muscle loss predict blood cancer outcomes?
- Smartwatch could spot nerve damage before it starts
- Can a Triple-Action antibody deepen remissions in myeloma?